Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ALTA-3
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- NCT03596866 ↗
- Completed
- Takeda
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ALTA-3 (crizotinib-resistant advanced ALK-positive NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ALTA-3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- ALK+ Advanced NSCLC
- Interventions
- Brigatinib; Alectinib
- Arms
- Brigatinib · Experimental
- Alectinib · Active comparator
- Enrollment
- 248
- Primary outcomes
- Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1
- Sponsor
- Takeda
- Start
- Apr 19, 2019
- Primary completion
- Feb 27, 2024
- Results posted
- Yes
- Registry record
- NCT03596866 · updated Sep 12, 2025
Publications
linked from the registry- Yang JC, Liu G, Lu S, He J, Burotto M, Ahn MJ, Kim DW, Liu X, Zhao Y, Vincent S, Yin J, Ma X, Lin HM, Popat S. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. J Thorac Oncol. 2023 Dec;18(12):1743-1755. doi: 10.1016/j.jtho.2023.08.010. Epub 2023 Aug 12. PubMed 37574132
- Popat S, Liu G, Lu S, Song G, Ma X, Yang JC. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncol. 2021 Nov;17(32):4237-4247. doi: 10.2217/fon-2021-0608. Epub 2021 Aug 23. PubMed 34423676